HRP20020332B1 - Oralne otopine koje sadrže galantamin i sladilo - Google Patents

Oralne otopine koje sadrže galantamin i sladilo

Info

Publication number: HRP20020332B1
Authority: HR; Croatia
Prior art keywords: sugar; solutions containing; oral solutions; containing galantamine; galantamine
Prior art date: 1999-10-26

Application number

HR20020332A

Other languages

English (en)

Croatian (hr)

Inventor

Karel Jozef Francois Marc

Mathilde Tony

Andre Eddy

Original Assignee

Janssen Pharmaceutica N.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-26

Filing date

2000-10-16

Publication date

2011-02-28

2000-10-16 Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.

2004-02-29 Publication of HRP20020332A2 publication Critical patent/HRP20020332A2/xx

2011-02-28 Publication of HRP20020332B1 publication Critical patent/HRP20020332B1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Addiction (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)

HR20020332A 1999-10-26 2000-10-16 Oralne otopine koje sadrže galantamin i sladilo HRP20020332B1 (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP99203512		1999-10-26
PCT/EP2000/010203 WO2001030318A1 (en)	1999-10-26	2000-10-16	Oral solution containing galanthamine and a sweetening agent

Publications (2)

Publication Number	Publication Date
HRP20020332A2 HRP20020332A2 (en)	2004-02-29
HRP20020332B1 true HRP20020332B1 (hr)	2011-02-28

Family

ID=8240778

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20020332A HRP20020332B1 (hr)	1999-10-26	2000-10-16	Oralne otopine koje sadrže galantamin i sladilo

Country Status (29)

Country	Link
EP (1)	EP1237539B1 (is)
JP (1)	JP2003512415A (is)
KR (1)	KR100502391B1 (is)
CN (1)	CN1200691C (is)
AR (1)	AR026243A1 (is)
AT (1)	ATE306904T1 (is)
AU (1)	AU780826C (is)
BG (1)	BG65792B1 (is)
BR (1)	BR0015025A (is)
CA (1)	CA2388830C (is)
CZ (1)	CZ301996B6 (is)
DE (1)	DE60023341T2 (is)
DK (1)	DK1237539T3 (is)
EA (1)	EA005683B1 (is)
EE (1)	EE05230B1 (is)
ES (1)	ES2250211T3 (is)
HR (1)	HRP20020332B1 (is)
HU (1)	HUP0203484A3 (is)
IL (2)	IL149310A0 (is)
IS (1)	IS2628B (is)
MX (1)	MXPA02004149A (is)
NO (1)	NO332096B1 (is)
PL (1)	PL201694B1 (is)
SI (1)	SI1237539T1 (is)
SK (1)	SK285643B6 (is)
TW (1)	TW592725B (is)
UA (1)	UA76095C2 (is)
WO (1)	WO2001030318A1 (is)
ZA (1)	ZA200203313B (is)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030162770A1 (en) *	2002-02-22	2003-08-28	Davis Bonnie M.	Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
CA2535613A1 (en)	2003-08-13	2005-02-24	Janssen Pharmaceutica, N.V.	Treatment of sleep disorders with cholinesterase inhibitors
US20050191349A1 (en) *	2003-12-31	2005-09-01	Garth Boehm	Galantamine formulations
US8709521B2 (en) *	2007-05-22	2014-04-29	The Coca-Cola Company	Sweetener compositions having enhanced sweetness and improved temporal and/or flavor profiles
BR112013018898B1 (pt) *	2011-01-27	2021-10-05	Neuren Pharmaceuticals Limited	Uso de ácido glicil-l-2-metilprolil-l-glutâmico e análogos do mesmo para o tratamento de transtornos do espectro do autismo
WO2014059363A1 (en) *	2012-10-11	2014-04-17	Antrim Pharmaceuticals Llc	Oral solution formulations of aripiprazole
JP6457582B2 (ja) *	2017-04-14	2019-01-23	エルメッドエーザイ株式会社	ガランタミン含有医薬組成物、並びに医薬組成物におけるガランタミンの苦味抑制方法、及びガランタミンの苦味抑制剤
CN117717558A (zh) *	2023-12-06	2024-03-19	艾威药业(珠海)有限公司	加兰他敏及其药学上可接受的盐在制备治疗眼部疾病的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0449247A2 (de) *	1990-03-29	1991-10-02	LTS Lohmann Therapie-Systeme GmbH & Co. KG	Galanthemin enthaltende pharmazeutische Formulierung zur Behandlung des Alkoholismus
EP0556057A1 (en) *	1992-02-14	1993-08-18	McNEIL-PPC, INC.	Aqueous pharmaceutical suspension for pharmaceutical actives
EP0653427A1 (en) *	1993-10-15	1995-05-17	Hoechst-Roussel Pharmaceuticals Incorporated	Galanthamine derivatives, a process for their preparation and their use as medicaments

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH10273435A (ja) *	1997-01-29	1998-10-13	Fujisawa Pharmaceut Co Ltd	内服用液剤

2000
- 2000-10-16 TW TW089121526A patent/TW592725B/zh not_active IP Right Cessation
- 2000-10-16 HU HU0203484A patent/HUP0203484A3/hu unknown
- 2000-10-16 UA UA2002054064A patent/UA76095C2/uk unknown
- 2000-10-16 SI SI200030782T patent/SI1237539T1/sl unknown
- 2000-10-16 EE EEP200200213A patent/EE05230B1/xx unknown
- 2000-10-16 SK SK530-2002A patent/SK285643B6/sk not_active IP Right Cessation
- 2000-10-16 BR BR0015025-8A patent/BR0015025A/pt not_active Application Discontinuation
- 2000-10-16 EA EA200200486A patent/EA005683B1/ru not_active IP Right Cessation
- 2000-10-16 AU AU13849/01A patent/AU780826C/en not_active Expired
- 2000-10-16 MX MXPA02004149A patent/MXPA02004149A/es active IP Right Grant
- 2000-10-16 EP EP00975872A patent/EP1237539B1/en not_active Expired - Lifetime
- 2000-10-16 WO PCT/EP2000/010203 patent/WO2001030318A1/en not_active Ceased
- 2000-10-16 PL PL362849A patent/PL201694B1/pl unknown
- 2000-10-16 KR KR10-2002-7003258A patent/KR100502391B1/ko not_active Expired - Lifetime
- 2000-10-16 JP JP2001532738A patent/JP2003512415A/ja active Pending
- 2000-10-16 DK DK00975872T patent/DK1237539T3/da active
- 2000-10-16 IL IL14931000A patent/IL149310A0/xx active IP Right Grant
- 2000-10-16 ES ES00975872T patent/ES2250211T3/es not_active Expired - Lifetime
- 2000-10-16 AT AT00975872T patent/ATE306904T1/de active
- 2000-10-16 HR HR20020332A patent/HRP20020332B1/xx not_active IP Right Cessation
- 2000-10-16 CA CA002388830A patent/CA2388830C/en not_active Expired - Lifetime
- 2000-10-16 CN CNB008147388A patent/CN1200691C/zh not_active Expired - Lifetime
- 2000-10-16 DE DE60023341T patent/DE60023341T2/de not_active Expired - Lifetime
- 2000-10-16 CZ CZ20021329A patent/CZ301996B6/cs not_active IP Right Cessation
- 2000-10-25 AR ARP000105621A patent/AR026243A1/es not_active Application Discontinuation
2002
- 2002-02-28 IS IS6291A patent/IS2628B/is unknown
- 2002-03-20 BG BG106534A patent/BG65792B1/bg unknown
- 2002-04-24 IL IL149310A patent/IL149310A/en unknown
- 2002-04-25 ZA ZA200203313A patent/ZA200203313B/xx unknown
- 2002-04-26 NO NO20022003A patent/NO332096B1/no not_active IP Right Cessation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0449247A2 (de) *	1990-03-29	1991-10-02	LTS Lohmann Therapie-Systeme GmbH & Co. KG	Galanthemin enthaltende pharmazeutische Formulierung zur Behandlung des Alkoholismus
EP0556057A1 (en) *	1992-02-14	1993-08-18	McNEIL-PPC, INC.	Aqueous pharmaceutical suspension for pharmaceutical actives
EP0653427A1 (en) *	1993-10-15	1995-05-17	Hoechst-Roussel Pharmaceuticals Incorporated	Galanthamine derivatives, a process for their preparation and their use as medicaments

Also Published As

Publication number	Publication date
MXPA02004149A (es)	2002-10-17
NO332096B1 (no)	2012-06-18
EA005683B1 (ru)	2005-04-28
CZ301996B6 (cs)	2010-09-01
HUP0203484A3 (en)	2004-12-28
EE05230B1 (et)	2009-12-15
HK1049619A1 (en)	2003-05-23
EP1237539B1 (en)	2005-10-19
CA2388830C (en)	2006-09-19
SI1237539T1 (sl)	2006-04-30
ES2250211T3 (es)	2006-04-16
KR20020026010A (ko)	2002-04-04
BR0015025A (pt)	2002-06-18
WO2001030318A1 (en)	2001-05-03
AU780826C (en)	2006-02-16
ATE306904T1 (de)	2005-11-15
EP1237539A1 (en)	2002-09-11
EA200200486A1 (ru)	2002-10-31
DE60023341T2 (de)	2006-07-27
CZ20021329A3 (cs)	2002-08-14
IS2628B (is)	2010-05-15
PL362849A1 (en)	2004-11-02
KR100502391B1 (ko)	2005-07-19
NO20022003D0 (no)	2002-04-26
DK1237539T3 (da)	2006-02-27
PL201694B1 (pl)	2009-04-30
JP2003512415A (ja)	2003-04-02
BG106534A (en)	2002-12-29
TW592725B (en)	2004-06-21
IL149310A0 (en)	2002-11-10
AR026243A1 (es)	2003-02-05
AU780826B2 (en)	2005-04-21
HUP0203484A2 (hu)	2003-02-28
CA2388830A1 (en)	2001-05-03
SK285643B6 (sk)	2007-05-03
ZA200203313B (en)	2003-11-26
SK5302002A3 (en)	2002-10-08
UA76095C2 (en)	2006-07-17
CN1382037A (zh)	2002-11-27
IL149310A (en)	2006-12-10
NO20022003L (no)	2002-06-18
IS6291A (is)	2002-02-28
CN1200691C (zh)	2005-05-11
DE60023341D1 (de)	2006-03-02
EE200200213A (et)	2003-06-16
HRP20020332A2 (en)	2004-02-29
BG65792B1 (bg)	2009-12-31
AU1384901A (en)	2001-05-08

Publication	Publication Date	Title
YU49354B (sh)	2005-09-19	Oralne tečne formulacije alendronata
MY135119A (en)	2008-02-29	Stabilized oral suspension formulation
WO2001041737A3 (en)	2002-01-03	Solid oral dosage form
HRP20020198B1 (hr)	2011-02-28	Formulacija moksifloksacina i kuhinjske soli
YU57600A (sh)	2003-10-31	Derivarti biciklične hidroksaminske kiseline
DE69909135D1 (de)	2003-07-31	Orale zubereitung zur bekämpfung von mundgeruch
EP1135173A4 (en)	2005-03-09	MEDICINAL AEROSOL FORMULATION
AP9801169A0 (en)	1999-08-05	N-hydroxy-B-sulfonyl propionamide derivatives.
HRP20060240T3 (hr)	2007-05-31	Intranazalni pripravak rotigotina
HUP0200895A3 (en)	2002-12-28	Benzimidazole derivatives of alpha-substituted carboxylic acids, pharmaceutical compositions containing them and their use
PL337794A1 (en)	2000-09-11	Pharmaceutic agent for oral administration containing an active substance and cyclodextrin
FR2677984B1 (fr)	1994-02-25	Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
HUP0200623A3 (en)	2002-10-28	4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors and pharmaceutical compositions containing them
MA26502A1 (fr)	2004-12-20	Analogues peptidiques de la lh-rh, leur utilisation et les compositions pharmaceutiques les contenant.
HUP0203935A3 (en)	2006-02-28	Sulfonamides and derivatives thereof that modulate the activity of endothelin, pharmaceutical compositions containing them and their use
DK1104289T3 (da)	2006-05-15	Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
HRP20010878B1 (en)	2007-03-31	Ziprasidone suspension
HUP9801414A2 (hu)	1999-01-28	Nátrium-alginátot és kálium-bikarbonátot tartalmazó folyékony vizes gyógyszerkészítmények
ZA200007415B (en)	2002-04-02	Amino acid derivatives and drugs containing the same as the active ingredient.
EP1221926A4 (en)	2009-07-15	PHARMACEUTICAL COMPOSITIONS WITH POOR SOLVENT MEDICAMENTS
HRP20020332B1 (hr)	2011-02-28	Oralne otopine koje sadrže galantamin i sladilo
ATE107853T1 (de)	1994-07-15	Orales, melatonin enthaltendes arzneimittel.
ZA200303113B (en)	2004-07-23	Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them.
CA2379314A1 (en)	2001-01-25	Tablet for sucking, containing ambroxol
DE69521122D1 (de)	2001-07-05	2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze

Legal Events

Date	Code	Title	Description
2004-02-29	A1OB	Publication of a patent application
2004-08-03	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2011-02-28	B1PR	Patent granted
2018-11-02	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20180928 Year of fee payment: 19
2019-11-15	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20191030 Year of fee payment: 20
2020-10-23	PB20	Patent expired after termination of 20 years	Effective date: 20201016